Search
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: breast. 48 results shown below.
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Complete title: A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (alpha-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Principal Investigator: William Gwin
Study Number: 8790
Phase: I
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients
Principal Investigator: Nora Disis, MD
Study Number: 9140
Phase: I
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Complete title: Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Principal Investigator: Li-Ming Fang
Study Number: 9701
Phase: III
Endocrine Response in Women With Invasive Lobular Breast Cancer
Complete title: A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer
Principal Investigator: Hannah Linden, MD
Study Number: 9743
Phase: II
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Complete title: Expanded Access Protocol with ABT-888 (Veliparib) in Patients with Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer
Principal Investigator: Jennifer Specht, MD
Study Number: 9763
Phase: N/A
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
Complete title: Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
Principal Investigator: Janice Kim, MD
Study Number: 9960
Phase: N/A
Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
Complete title: The Evaluation of a Work Intervention to Facilitate Work Maintenance or Re-entry to the Workforce for Breast Cancer Patients
Principal Investigator: Rachel Yung
Study Number: 9993
Phase: N/A
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Complete title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: Janice Kim, MD
Study Number: A011202
Phase: III
Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer with Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)
Principal Investigator: Jennifer Specht, MD
Study Number: RG1003846
Phase: I
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Complete title: A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR" Study
Principal Investigator: Natasha Hunter
Study Number: RG1004199
Phase: II
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Complete title: A Phase II Study of Concurrent WOKVAC Vaccination with Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy
Principal Investigator: William Gwin
Study Number: RG1005296
Phase: II
Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study
Complete title: IMPACT: Improving Access to Cancer Survivorship via Telehealth
Principal Investigator: Eric Chow, MD
Study Number: RG1005815
Phase: N/A
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Complete title: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Principal Investigator: Jennifer Specht, MD
Study Number: RG1005902
Phase: II
Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization
Complete title: Implementation Studio, an Innovative, Structured Approach to Facilitate Rural Community-Based Organizations' Adaption and Implementation of Evidence-Based Interventions
Principal Investigator: Linda Ko
Study Number: RG1006143
Phase: N/A
Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors
Complete title: Testing a Scalable Nutrition and Physical Activity Program for Breast Cancer Survivors: A Dose-Finding Pilot Study
Principal Investigator: Heather Greenlee, ND
Study Number: RG1006427
Phase: II
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Complete title: A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Principal Investigator: Natasha Hunter
Study Number: RG1006860
Phase: I/II
Olaparib In Metastatic Breast Cancer
Complete title: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Principal Investigator: Shaveta Vinayak
Study Number: TBCRC048
Phase: II
Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications
Complete title: Defining the Molecular Profile of Breast Cancer in Uganda and its Clinical Implications
Principal Investigator: Manoj Menon
Study Number: U025
Phase: I
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Principal Investigator: Gabriela Chiorean
Study Number: 9078
Phase: I
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Principal Investigator: David Maloney, MD, PhD
Study Number: 9330
Phase: I
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Complete title: A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Principal Investigator: Nora Disis, MD
Study Number: 9863
Phase: II
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1)
Complete title: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Principal Investigator: Jennifer Specht, MD
Study Number: Palbo T-DM1
Phase: II
Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants (ACE)
Complete title: Acute Effects of Exercise on Breast Cancer Biomarkers (ACE) Study
Principal Investigator: Anne McTiernan, MD, PhD
Study Number: RG1003977
Phase: N/A
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Complete title: [F18] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
Principal Investigator: Hannah Linden, MD
Study Number: 9594
Phase: II
Breast Cancer WEight Loss Study (BWEL Study)
Complete title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Principal Investigator: Rachel Yung
Study Number: A011401
Phase: III
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Complete title: Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Principal Investigator: Richard Cheng, MD, MSc
Study Number: RG1005231
Phase: N/A
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Complete title: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE
Principal Investigator: Jennifer Specht, MD
Study Number: RG1007840
Phase: II
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
Complete title: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Principal Investigator: Janice Kim, MD
Study Number: RG1007851
Phase: II
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Complete title: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Principal Investigator: Rachel Yung
Study Number: S1501
Phase: III
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Complete title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Principal Investigator: Sylvia Lee, MD
Study Number: 10501
Phase: I
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
Principal Investigator: Gabriela Chiorean
Study Number: 20160524
Phase: I
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Principal Investigator: Kit Wong
Study Number: 20171486
Phase: I
Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Complete title: A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer
Principal Investigator: Hannah Linden, MD
Study Number: 20171553
Phase: I/II
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Principal Investigator: Nora Disis, MD
Study Number: 20181578
Phase: I
Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer
Complete title: A PHASE 1B, MULTICENTER, TWO-PART, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2-EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER
Principal Investigator: Evan Yu, MD
Study Number: RG1003438
Phase: I
A Study of ZN-c5 in Subjects With Breast Cancer
Complete title: A PHASE I OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ZN-c5 ALONE AND IN COMBINATION WITH PALBOCICLIB IN SUBJECTS WITH PREVIOUSLY TREATED ESTROGEN-RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 NEGATIVE ADVANCED BREAST CANCER
Principal Investigator: Hannah Linden, MD
Study Number: RG1003570
Phase: I/II
A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)
Complete title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and in Combination with NKTR-214 plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Principal Investigator: Shailender Bhatia, MD
Study Number: RG1004346
Phase: I/II
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)
Complete title: A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
Principal Investigator: Rachel Yung
Study Number: RG1004489
Phase: III
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Complete title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Principal Investigator: Shaveta Vinayak
Study Number: RG1005141
Phase: I/II
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Complete title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Principal Investigator: Ryan Lynch
Study Number: RG1006339
Phase: I/II
A Study of ZN-c5 in Participants With Breast Cancer
Complete title: A Phase 1 Open-Label, Multicenter Study to Evaluate
Biomarkers for ZN-c5 in Subjects with Estrogen
Receptor-Positive, Human Epidermal Growth Factor
Receptor 2-Negative Breast Cancer
Principal Investigator: Hannah Linden, MD
Study Number: RG1006541
Phase: I
9-ING-41 in Patients With Advanced Cancers
Complete title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Principal Investigator: Andrew Coveler, MD
Study Number: RG1006626
Phase: I/II
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Complete title: PHASE 1/2a DOSE ESCALATION AND EXPANSION STUDY
EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC,
PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF
PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH
ENDOCRINE THERAPY
Principal Investigator: Shaveta Vinayak
Study Number: RG1007255
Phase: I/II
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Complete title: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Principal Investigator: Kalyan Banda
Study Number: RG1007753
Phase: I
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Complete title: AN EXPANDED ACCESS, SINGLE-ARM, MULTICENTER STUDY TO PROVIDE AT HOME SUBCUTANEOUS ADMINISTRATION OF PERTUZUMAB AND TRASTUZUMAB FIXED-DOSE COMBINATION (PH FDC SC) FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER DURING THE COVID-19 PANDEMIC
Principal Investigator: Natasha Hunter
Study Number: RG1121133
Phase: N/A
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)
Complete title: A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting
Principal Investigator: Natasha Hunter
Study Number: RG1121177
Phase: I/II
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Complete title: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Principal Investigator: Catherine Albert, MD
Study Number: SC-4016
Phase: I/II